Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023)

Novartis Ag has disclosed Liabilities from Discontinued Operations across 7 years of filings, most recently posting $8.8 billion for Q3 2023.

• In Q3 2023, Liabilities from Discontinued Operations changed N/A year-over-year to $8.8 billion; the TTM figure through Sep 2023 stood at $8.8 billion (changed N/A YoY), while the FY2022 annual figure was $28.7 billion, changed N/A from the prior year.
• Liabilities from Discontinued Operations came in at $8.8 billion for Q3 2023 at Novartis Ag, up from $34.0 million in the prior quarter.
• In the past five years, Liabilities from Discontinued Operations ranged from a high of $28.7 billion in Q4 2022 to a low of $24.0 million in Q3 2019.
• Average Liabilities from Discontinued Operations over 3 years is $6.1 billion, with a median of $50.0 million recorded in 2019.
• The largest YoY upside for Liabilities from Discontinued Operations was 39.22% in 2019 against a maximum downside of 68.42% in 2019.
• Over 3 years, Liabilities from Discontinued Operations stood at $31.0 million in 2019, then surged by 92338.71% to $28.7 billion in 2022, then sank by 69.33% to $8.8 billion in 2023.
• Per Business Quant data, the three most recent Liabilities from Discontinued Operations figures were $8.8 billion in Q3 2023, $34.0 million in Q2 2023, and $28.7 billion in Q4 2022.